Microsoft Recommends Philips SpeechMike Premium Touch as the Successor to Nuance PowerMic

7.5.2025 14:00:00 CEST | Business Wire | Press Release

Speech Processing Solutions, global leader in professional dictation solutions under the Philips brand, today announced that the Philips SpeechMike Premium Touch has been officially recognized by Microsoft as the recommended successor to the soon-to-be-retired Nuance PowerMic series.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507643740/en/

The Philips SpeechMike Premium Touch.

As the only microphone recommended by Microsoft for PowerMic replacement, the Philips SpeechMike Premium Touch delivers seamless, plug-and-play compatibility with many Nuance speech recognition solutions, including Dragon Medical One, Dragon Professional Anywhere, Dragon Legal Anywhere, and some versions of PowerScribe offering medical, legal and business professionals a superior alternative for uninterrupted documentation workflows.

With an intuitive button layout mirroring the PowerMic, the Philips SpeechMike Premium Touch offers users a familiar, yet enhanced dictation experience to enable effortless transitions. Already in use by millions of medical, legal and business professionals worldwide, the Philips SpeechMike Premium Touch offers:

Compatibility with Dragon Medical One, Dragon Professional Anywhere, Dragon Legal Anywhere, and some versions of PowerScribe, as well as other legacy software such as Dragon NaturallySpeaking, Dragon Medical Practice Edition, and Winscribe
Pre-configured Dragon function keys for convenient speech recognition control
Studio-quality microphone with noise reduction for unprecedented accuracy in speech recognition
Ergonomic design and hygienic housing, ideal for long-shift use and clinical work environments
Advanced touch sensor navigation replaces the need to switch to a mouse

“With the PowerMic now being retired in the coming weeks, organizations must move quickly to maintain continuity in documentation,” said Dr. Thomas Brauner, CEO at Speech Processing Solutions. “The Philips SpeechMike Premium Touch is delivering both familiarity and unprecedented quality in speech recognition accuracy. I am delighted to be able to offer the Philips SpeechMike – the leading and most widely used dictation microphone in the world – to all existing PowerMic users.”

The Philips SpeechMike Premium Touch is available now through professional distribution channels.

Speech Processing Solutions (SPS):

Speech Processing Solutions (SPS) is the global leader in AI-powered dictation and transcription solutions. Active in over 50 countries with more than 4 million users and a network of 1,000+ partners, SPS develops award-winning speech-to-text technologies and devices under the Philips brand. Headquartered in Vienna, Austria, SPS is globally active with offices in Australia, Canada, Belgium, France, Germany, the UK, and the US.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250507643740/en/

Contacts

Press Contact:
Speech Processing Solutions
Alice Elt
Content & PR Manager
Email: alice.elt@speech.com
www.philips.com/dictation -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.philips.com
%2Fdictation&esheet=54250519&newsitemid=20250507643740&lan=en-US&anchor=www.phil
ips.com%2Fdictation&index=1&md5=4ebfbd075bc4030d7af0e4df6074c7f7 |
www.speechlive.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.speechlive.
com%2F&esheet=54250519&newsitemid=20250507643740&lan=en-US&anchor=www.speechlive
.com&index=2&md5=487585fc307509b39270f33138c5b480

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom